盐酸罗格列酮对糖尿病肾病大鼠血清TNF-αIL-6MCP-1表达的影响

摘要

目的：观察噻唑烷二酮类药物盐酸罗格列酮对STZ诱导的糖尿病肾病（DN）大鼠血清TNF-α、IL-6、MCP-1表达的影响及对肾脏的保护作用。方法45只雄性SD大鼠随机分为正常对照组、DN模型组（模型组）和DN罗格列酮用药组（罗格列酮组）三组，各15例，罗格列酮组对DN造模大鼠用4mg/（kg.d）罗格列酮无菌水混悬液灌胃。8周末测各组大鼠24h尿蛋白、尿素氮（BUN）、血肌酐（Scr）、空腹血糖（FBG）及TNF-α、IL-6、MCP-1表达水平。结果模型组大鼠各指标较正常对照组均明显升高（P<0.01）；罗格列酮组与模型组比较，各各指标以有下降（P<0.01或P<0.05）。结论盐酸罗格列酮能改善24h尿蛋白、BUN、Scr，能降低血清TNF-α、IL-6、MCP-1水平，表明盐酸罗格列酮对DN患者肾脏有一定的保护作用。%Objective To investigate the protecting effects of rosiglitazone hydrochloride on diabetic nephropathy and the change of the expression of TNF-α、IL-6、MCP-1. Methods 45 male SD rats the experimental rats were divided into three groups:normal group(n=15),model group(n=15)and treatment groups(n=15); fast blood gluocose(FBG),The urine in 24 h and blood samples were collected after the treatment for 8weeks. The rats were killed and the pathological changes of kidney were observed,fast blood insulin were measured by ELISA. Results In the model group,rosiglitazone,BG、BUN and Scr were higher than normal group(P<0.01),there was no difference in the fasting blood glucose between the model group and the rosiglitazone group(P>0.05);The rosiglitazone group was significantly lower than model group in BUN and Scr(P<0.01);TNF-α、IL-6 andMCP-1 were significantly reduced(P<0.01). Conclusion Rosiglitazone hydrochloride can not only improve The 24 urine protein、serum creatinine and blood urea nitrogen; It can significantly reduce serum TNF-α、IL-6 and MCP-1 level,which indicates that it has protective effect on kidney in diabetic nephropathy of rats.